1x7bt3DfIrC4JoGfQsAiDHiS_bNoLXqyh_uc4_B5ytmk
Warning: session_start() [function.session-start]: Cannot send session cookie - headers already sent by (output started at /home/kocp/html/sub06/1x7bt3DfIrC4JoGfQsAiDHiS_bNoLXqyh_uc4_B5ytmk.php:2) in /home/kocp/html/admin/lib/lib.php on line 12

Warning: session_start() [function.session-start]: Cannot send session cache limiter - headers already sent (output started at /home/kocp/html/sub06/1x7bt3DfIrC4JoGfQsAiDHiS_bNoLXqyh_uc4_B5ytmk.php:2) in /home/kocp/html/admin/lib/lib.php on line 12

Warning: Cannot modify header information - headers already sent by (output started at /home/kocp/html/sub06/1x7bt3DfIrC4JoGfQsAiDHiS_bNoLXqyh_uc4_B5ytmk.php:2) in /home/kocp/html/admin/lib/function.php on line 2

Warning: Cannot modify header information - headers already sent by (output started at /home/kocp/html/sub06/1x7bt3DfIrC4JoGfQsAiDHiS_bNoLXqyh_uc4_B5ytmk.php:2) in /home/kocp/html/admin/lib/function.php on line 1466

Warning: Cannot modify header information - headers already sent by (output started at /home/kocp/html/sub06/1x7bt3DfIrC4JoGfQsAiDHiS_bNoLXqyh_uc4_B5ytmk.php:2) in /home/kocp/html/head.lib.php on line 7
ÀǾàÇ°Ç°Áú¿¬±¸Àç´Ü

>

Á¦5ȸ Ç°Áú±ÔÁ¦°úÇÐ ±¹Á¦ ¿þºñ³ª ÄÁÆÛ·±½º

NIFDS -PMRJ -RFPQ ÇÕµ¿ ½ÉÆ÷Áö¾ö

2020³â 11¿ù 20ÀÏ(±Ý) ZOOM Webinar

½Ã°£ ³»¿ë
08:30~09:00 µî·Ï
09:00~09:20 °³È¸½Ä
°³È¸»ç ÀǾàÇ°Ç°Áú¿¬±¸Àç´Ü ȸÀå ÀüÀα¸
°Ý·Á»ç ½ÄÇ°ÀǾàÇ°¾ÈÀüÆò°¡¿ø
ÀÇ·áÁ¦Ç°¿¬±¸ºÎ ºÎÀå ¹ÚÀ±ÁÖ
Ãà»ç 1 Çѱ¹Á¦¾à¹ÙÀÌ¿ÀÇùȸ ȸÀå ¿øÈñ¸ñ
Ãà»ç 2 PMRJ Àü¹« ½Ã°ÔÅ° Ã÷´Ù
09:20~10:35 NIFDS ¼¼¼Ç : Quality Initiatives and International Harmonization
Ç°Áú»óÀÇ °úÁ¦¿Í ±¹Á¦Á¶È­
ÁÂÀå : À嵿Áø (°­¿ø´ëÇб³)
09:20~09:50 Recent trends in drug quality reviews
ÀǾàÇ° Ç°Áú½É»çÀÇ ÃÖ±Ù µ¿Çâ
±è¹ÌÁ¤ °úÀå
½ÄÇ°ÀǾàÇ°¾ÈÀüÆò°¡¿ø ÀǾàÇ°±Ô°Ý°ú
09:55~10:35 Control and perspectives of hazard impurities in drug products
ÀǾàÇ° À¯ÇØ ºÒ¼ø¹°ÀÇ °ü¸® ¹× Àü¸Á
±è³²Èñ ÁÖ¹«°ü
½ÄÇ°ÀǾàÇ°¾ÈÀüÆò°¡¿ø ÀǾàÇ°¿¬±¸°ú
10:40~13:40 PMRJ ¼¼¼Ç : Control Strategy and Practices of Mutagenic Impurities in Japan
ÀϺ»ÀÇ º¯ÀÌ¿ø¼º ºÒ¼ø¹° °ü¸® Àü·« ¹× ½ÇÁ¦
¿À°Å³ªÀÌÀú : ½Ã°ÔÅ° Ã÷´Ù (PMRJ, Japan)
ÁÂÀå : °­Á¾¼º (Ãæ³²´ëÇб³)
10:40~11:20 Assessment and control of mutagenic impurities in pharmaceuticals
¿ÏÁ¦ ÀǾàÇ°ÀÇ º¯ÀÌ¿ø¼º ºÒ¼ø¹° Æò°¡ ¹× °ü¸®
Masamitsu Honma, Ph.D.
Deputy Director General, NIHS, Japan
11:25~12:05 Recent advances and challenges in the analysis of mutagenic impurities in pharmaceutical products
¿ÏÁ¦ ÀǾàÇ°ÀÇ º¯ÀÌ¿ø¼º ºÒ¼ø¹° ºÐ¼®ÀÇ ÃÖ±Ù ¹ßÀü°ú °úÁ¦
Eiichi Yamamoto, Ph.D.
Section Chief, Drug Division, NIHS, Japan
12:05~13:00 Áß½Ä
13:00~13:40 Methods and issues of mutagenicity and carcinogenicity evaluation of pharmaceutical impurities based on ICH M7 guideline-From the viewpoints of practices for pharmaceutical businesses-
ICH M7 °¡À̵å¶óÀο¡ ±Ù°ÅÇÑ ÀǾàÇ° ºÒ¼ø¹°ÀÇ º¯ÀÌ¿ø¼º°ú ¹ß¾Ï¼º Æò°¡ ¹æ¹ý ¹× °úÁ¦ - Á¦¾à»ê¾÷ÀÇ ½Ç¹« °üÁ¡¿¡¼­
Tsukasa KIKUNO, Ph.D.
President and CEO, PhiAS Co., Ltd., Japan
13:45~14:25 Special Invited Lecture ÁÂÀå : Á¶Á¤È¯ (¼÷¸í¿©ÀÚ´ëÇб³)
13:45~14:25 Development, control and current status of JP reference standards
ÀϺ»¾àÀü Ç¥ÁØÇ°ÀÇ °³¹ß, °ü¸® ¹× ÇöȲ
Yukari Nakagawa, Ph.D.
Director, Department of Reference Standard, PMRJ, Japan
14:30~17:40 RFPQ ¼¼¼Ç ¥² : Control and Practices of Mutagenic Impurities in Pharmaceutical Products
ÀǾàÇ°ÀÇ º¯ÀÌ¿ø¼º ºÒ¼ø¹° °ü¸®¿Í ½Çü
ÁÂÀå : Ȳ¼ºÁÖ (¿¬¼¼´ëÇб³)
14:30~15:10 ICH Q9 : Quality risk management
ICH Q9 : Ç°Áú ¸®½ºÅ© °ü¸®
ÀÓÈñ±Õ »çÀå
¾Ëº¸Á¨ÄÚ¸®¾Æ
15:10~15:30 ÈÞ½Ä ½Ã°£
15:30~16:10 Isolation and purification of impurities in drug substances
¿ø·á ÀǾàÇ° Áß ºÒ¼ø¹°ÀÇ ºÐ¸® Á¤Á¦
°¨°æÇö ¿¬±¸¼ÒÀå
¹öµ§Æ®Å×Å©³î·ÎÁö
16:15~16:55 Determination of nitrosamine and unknown impurity ID using LC-HR/AM Orbitrap with 2D LC
2D LC¿Í ÇÔ²² LC-HR / AM OrbitrapÀ» ÀÌ¿ëÇÑ ´ÏÆ®·Î»ç¹Î ÃøÁ¤ ¹× ¹ÌÁö ºÒ¼ø¹°ÀÇ È®ÀÎ
°íÈÖ¿ø ¼ö¼®
½á¸ðÇǼŻçÀ̾ðƼÇÈÄÚ¸®¾Æ
17:00~17:40 Current status of the pharmaceutical industry and case studies by mandatory submission of mutagenic impurities data in Korea
±¹³» º¯ÀÌ¿ø¼º ºÒ¼ø¹° ÀÚ·á Àǹ« Á¦Ãâ¿¡ µû¸¥ Á¦¾à »ê¾÷ ÇöȲ ¹× »ç·Ê ¿¬±¸
Á¶È¿Çö ÆÀÀå
ÀϾç¾àÇ°
17:40~ ¸ÎÀ½¸» ±è¹ÌÁ¤ °úÀå
½ÄÇ°ÀǾàÇ°¾ÈÀüÆò°¡¿ø ÀǾàÇ°±Ô°Ý°ú